{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:01:06Z","timestamp":1793246466648,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A high incidence of somatically acquired point mutations in the AML1\/RUNX1 gene has been reported in poorly differentiated acute myeloid leukemia (AML, M0) and in radiation-associated and therapy-related myelodysplastic syndrome (MDS) or AML. The vast majority of AML1 mutations identified in these diseases were localized in the amino (N)\u2013terminal region, especially in the DNA-binding Runt homology domain. In this report, we show that AML1 point mutations were found in 26 (23.6%) of 110 patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt), and AML following MDS (defined these 3 disease categories as MDS\/AML). Among them, 9 (8.2%) mutations occurred in the carboxy (C)\u2013terminal region, which were exclusively found in MDS\/AML and were strongly correlated with sporadic MDS\/AML. All patients with MDS\/AML with an AML1 mutation expressed wild-type AML1 protein and had a significantly worse prognosis than those without AML1 mutations. Most AML1 mutants lost trans-activation potential, regardless of their DNA binding potential. These data suggested that AML1 point mutation is one of the major driving forces of MDS\/AML, and these mutations may represent a distinct clinicopathologic-genetic entity.<\/jats:p>","DOI":"10.1182\/blood-2003-09-3074","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T01:14:02Z","timestamp":1069118042000},"page":"2316-2324","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":234,"title":["High incidence of somatic mutations in the AML1\/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia"],"prefix":"10.1182","volume":"103","author":[{"given":"Hironori","family":"Harada","sequence":"first","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Harada","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Niimi","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Kyo","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Inaba","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; the Department of Hematology\/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; and the Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222262096200_REF1","doi-asserted-by":"crossref","unstructured":"Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278: 1059-1064.","DOI":"10.1126\/science.278.5340.1059"},{"key":"2020021222262096200_REF2","doi-asserted-by":"crossref","unstructured":"Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol.1999; 106: 296-308.","DOI":"10.1046\/j.1365-2141.1999.01377.x"},{"key":"2020021222262096200_REF3","doi-asserted-by":"crossref","unstructured":"Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1\/PEBP2\u03b1B gene associated with myeloblastic leukemias. Blood. 1999;93: 1817-1824.","DOI":"10.1182\/blood.V93.6.1817.406k36_1817_1824"},{"key":"2020021222262096200_REF4","doi-asserted-by":"crossref","unstructured":"Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1\/PEBP2\u03b1B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96: 2862-2869.","DOI":"10.1182\/blood.V96.8.2862"},{"key":"2020021222262096200_REF5","doi-asserted-by":"crossref","unstructured":"Langabeer SE, Gale RE, Rollinson SJ, Morgan GJ, Linch DC. Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer. 2002;34: 24-32.","DOI":"10.1002\/gcc.10031"},{"key":"2020021222262096200_REF6","doi-asserted-by":"crossref","unstructured":"Silva FP, Morolli B, Storlazzi CT, et al. Identification of RUNX1\/AML1 as a classical tumor suppressor gene. Oncogene.2003;22: 538-547.","DOI":"10.1038\/sj.onc.1206141"},{"key":"2020021222262096200_REF7","doi-asserted-by":"crossref","unstructured":"Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome\/acute myeloid leukemia. Blood. 2003;101: 673-680.","DOI":"10.1182\/blood-2002-04-1010"},{"key":"2020021222262096200_REF8","doi-asserted-by":"crossref","unstructured":"Song W-J, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet.1999;23: 166-175.","DOI":"10.1038\/13793"},{"key":"2020021222262096200_REF9","doi-asserted-by":"crossref","unstructured":"Buijs A, Poddighe P, van Wijk R, et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood. 2001;98: 2856-2858.","DOI":"10.1182\/blood.V98.9.2856"},{"key":"2020021222262096200_REF10","doi-asserted-by":"crossref","unstructured":"Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1\/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99: 1364-1372.","DOI":"10.1182\/blood.V99.4.1364"},{"key":"2020021222262096200_REF11","doi-asserted-by":"crossref","unstructured":"Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runx1)-CBF\u03b2 complex functions as a DNA-induced molecular clamp. Nat Struct Biol.2001;8: 371-378.","DOI":"10.1038\/86264"},{"key":"2020021222262096200_REF12","doi-asserted-by":"crossref","unstructured":"Tahirov TH, Inoue-Bungo-T, Morii H, et al. Structural analysis of DNA recognition by the AML1\/Runx-1 runt domain and its allosteric control by CBF\u03b2. Cell. 2001;104: 755-767.","DOI":"10.1016\/S0092-8674(01)00271-9"},{"key":"2020021222262096200_REF13","doi-asserted-by":"crossref","unstructured":"Berardi MJ, Sun C, Zehr M, et al. The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure Fold Des.1999;7: 1247-1256.","DOI":"10.1016\/S0969-2126(00)80058-1"},{"key":"2020021222262096200_REF14","unstructured":"Nagata T, Gupta V, Sorce D, et al. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2\/CBF Runt domain. Nat Struct Biol.1999;7: 615-619."},{"key":"2020021222262096200_REF15","doi-asserted-by":"crossref","unstructured":"Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat.2002;19: 209-216.","DOI":"10.1002\/humu.10043"},{"key":"2020021222262096200_REF16","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol.1976;33: 451-458.","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"2020021222262096200_REF17","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol.1982;51: 188-189.","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"2020021222262096200_REF18","unstructured":"Mitelman F, ed. An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 1995."},{"key":"2020021222262096200_REF19","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Fujii M, Hayashi K, et al. The chimeric protein, PEBP2 beta\/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation. Oncogene.1998;17: 699-708.","DOI":"10.1038\/sj.onc.1201985"},{"key":"2020021222262096200_REF20","doi-asserted-by":"crossref","unstructured":"Zhang D-E, Hetherington CJ, Meyers S, et al. CCAAT enhancer-binding protein (C\/EBP) and AML1 (CBF\u03b12) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol.1996;16: 1231-1240.","DOI":"10.1128\/MCB.16.3.1231"},{"key":"2020021222262096200_REF21","doi-asserted-by":"crossref","unstructured":"Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res.1991;19: 2499.","DOI":"10.1093\/nar\/19.9.2499"},{"key":"2020021222262096200_REF22","doi-asserted-by":"crossref","unstructured":"Harada Y, Harada H, Downing JR, Kimura A. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Biochem Biophys Res Commun.2001;284: 714-722.","DOI":"10.1006\/bbrc.2001.5005"},{"key":"2020021222262096200_REF23","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc.1958;53: 659-663."},{"key":"2020021222262096200_REF24","doi-asserted-by":"crossref","unstructured":"Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96: 3154-3160.","DOI":"10.1182\/blood.V96.9.3154"},{"key":"2020021222262096200_REF25","doi-asserted-by":"crossref","unstructured":"Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)\/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2\/CBFbeta-SMMHC fusion protein inhibits PEBP2\/CBF-mediated transactivation. Mol Cell Biol.1998;18: 4252-4261.","DOI":"10.1128\/MCB.18.7.4252"},{"key":"2020021222262096200_REF26","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"2020021222262096200_REF27","doi-asserted-by":"crossref","unstructured":"Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95: 726-727.","DOI":"10.1182\/blood.V95.2.726"},{"key":"2020021222262096200_REF28","doi-asserted-by":"crossref","unstructured":"Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol.2003;121: 775-777.","DOI":"10.1046\/j.1365-2141.2003.04362.x"},{"key":"2020021222262096200_REF29","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3: 173-183.","DOI":"10.1016\/S1535-6108(03)00003-5"},{"key":"2020021222262096200_REF30","unstructured":"Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndrome. Semin Hematol.1996;33: 127-138."},{"key":"2020021222262096200_REF31","doi-asserted-by":"crossref","unstructured":"Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol.2001;73: 429-437.","DOI":"10.1007\/BF02994004"},{"key":"2020021222262096200_","doi-asserted-by":"crossref","unstructured":"Carnicer MJ, Nomdedeu JF, Lasa A, et al. AML-1 mutations outside the RUNT domain: description of two cases in myeloid malignancies. Leukemia.2002;16: 2329-2332.","DOI":"10.1038\/sj.leu.2402656"},{"key":"2020021222262096200_REF33","doi-asserted-by":"crossref","unstructured":"Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J.1995;14: 341-350.","DOI":"10.1002\/j.1460-2075.1995.tb07008.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/6\/2316\/1696311\/zh800604002316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/6\/2316\/1696311\/zh800604002316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:26:33Z","timestamp":1581564393000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/6\/2316\/18381\/High-incidence-of-somatic-mutations-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,15]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-09-3074","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,15]]}}}